BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Sanofi SA

Gesloten

SectorGezondheidszorg

92.54 -0.88

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

92.18

Max

94.26

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.3B

499M

Verkoop

-6.5B

7.6B

K/W

Sectorgemiddelde

20.663

57.333

EPS

1.31

Dividendrendement

4.32

Winstmarge

6.539

Werknemers

82,878

EBITDA

-3.7B

563M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+22.28% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.32%

2.63%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-20B

111B

Vorige openingsprijs

93.42

Vorige sluitingsprijs

92.54

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Sanofi SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2025, 08:52 UTC

Winsten

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24 apr 2025, 05:44 UTC

Winsten

Sanofi Sales, Profit Beat Expectations

9 apr 2025, 06:00 UTC

Acquisities, Fusies, Overnames

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

20 mrt 2025, 06:43 UTC

Acquisities, Fusies, Overnames

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

24 apr 2025, 12:54 UTC

Marktinformatie
Winsten

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24 apr 2025, 10:06 UTC

Marktinformatie
Winsten

Sanofi Starts the Year Strong -- Market Talk

10 apr 2025, 12:06 UTC

Marktinformatie
Acquisities, Fusies, Overnames

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

10 apr 2025, 09:10 UTC

Populaire aandelen

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

9 apr 2025, 10:49 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

9 apr 2025, 08:19 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

9 apr 2025, 06:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

9 apr 2025, 06:46 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

4 apr 2025, 09:07 UTC

Populaire aandelen

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

3 apr 2025, 07:51 UTC

Marktinformatie

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2 apr 2025, 13:44 UTC

Marktinformatie

Santander Push Into Canada on the Cards -- Market Talk

2 apr 2025, 09:27 UTC

Populaire aandelen

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mrt 2025, 06:19 UTC

Marktinformatie
Winsten

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 mrt 2025, 10:08 UTC

Marktinformatie

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 mrt 2025, 09:00 UTC

Top Nieuws

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 mrt 2025, 06:05 UTC

Acquisities, Fusies, Overnames

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 mrt 2025, 06:05 UTC

Acquisities, Fusies, Overnames

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 mrt 2025, 06:04 UTC

Acquisities, Fusies, Overnames

Sanofi to Pay $600M Upfront

20 mrt 2025, 06:02 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 mrt 2025, 06:00 UTC

Acquisities, Fusies, Overnames

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 mrt 2025, 09:33 UTC

Populaire aandelen

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 mrt 2025, 23:00 UTC

Top Nieuws

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 mrt 2025, 09:50 UTC

Winsten

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 mrt 2025, 09:49 UTC

Winsten

Santander Increased 2024 Cash Payments by 19%

24 feb 2025, 08:56 UTC

Marktinformatie
Winsten

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 feb 2025, 08:30 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Peer Vergelijking

Prijswijziging

Sanofi SA Prognose

Koersdoel

By TipRanks

22.28% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 114.144 EUR  22.28%

Hoogste 127 EUR

Laagste 83.729 EUR

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sanofi SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

10

Buy

4

Hold

0

Sell

Technische score

By Trading Central

91.62 / 93.4Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.